Novavax Other Current Assets vs Total Current Liabilities Analysis

NVAX Stock  USD 9.11  0.09  1.00%   
Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Other Current Assets and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Other Current Assets vs Total Current Liabilities

Other Current Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Other Current Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Novavax's Other Current Assets and Total Current Liabilities is 0.58. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Other Current Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Novavax are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Other Current Assets i.e., Novavax's Other Current Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.58
Relationship DirectionPositive 
Relationship StrengthWeak

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Total Current Liabilities

Total Current Liabilities is an item on Novavax balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novavax are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).

Novavax fundamental ratios Correlations

0.770.94-0.550.86-0.89-0.910.930.940.890.790.950.920.780.930.960.850.990.880.77-0.460.59-0.410.63-0.370.33
0.770.9-0.890.91-0.68-0.90.920.710.880.830.670.850.430.850.890.920.70.560.66-0.350.38-0.320.27-0.260.02
0.940.9-0.750.86-0.9-0.920.960.940.870.790.910.880.580.890.980.860.920.760.67-0.40.56-0.410.5-0.360.21
-0.55-0.89-0.75-0.740.420.79-0.72-0.52-0.71-0.75-0.44-0.69-0.21-0.69-0.76-0.75-0.48-0.4-0.620.35-0.430.210.00.15-0.19
0.860.910.86-0.74-0.65-0.960.910.70.990.920.680.970.710.960.921.00.780.740.87-0.430.39-0.360.38-0.30.14
-0.89-0.68-0.90.42-0.650.69-0.83-0.94-0.67-0.59-0.94-0.69-0.5-0.7-0.83-0.64-0.91-0.76-0.410.23-0.380.48-0.570.46-0.03
-0.91-0.9-0.920.79-0.960.69-0.93-0.79-0.97-0.91-0.77-0.98-0.72-0.99-0.97-0.96-0.85-0.77-0.890.5-0.570.34-0.410.28-0.33
0.930.920.96-0.720.91-0.83-0.930.890.910.770.870.90.670.920.960.910.890.680.7-0.410.55-0.40.6-0.360.17
0.940.710.94-0.520.7-0.94-0.790.890.720.610.990.770.630.790.910.690.970.760.57-0.40.67-0.410.68-0.390.35
0.890.880.87-0.710.99-0.67-0.970.910.720.930.710.990.740.980.930.990.820.790.89-0.440.41-0.350.39-0.290.19
0.790.830.79-0.750.92-0.59-0.910.770.610.930.580.930.570.90.860.930.710.830.87-0.40.26-0.360.09-0.290.15
0.950.670.91-0.440.68-0.94-0.770.870.990.710.580.760.660.790.880.670.980.770.55-0.40.64-0.40.72-0.380.32
0.920.850.88-0.690.97-0.69-0.980.90.770.990.930.760.790.990.950.970.860.840.92-0.480.48-0.390.43-0.340.29
0.780.430.58-0.210.71-0.5-0.720.670.630.740.570.660.790.80.680.690.760.690.8-0.50.56-0.360.73-0.330.49
0.930.850.89-0.690.96-0.7-0.990.920.790.980.90.790.990.80.960.960.870.820.91-0.50.54-0.340.47-0.280.33
0.960.890.98-0.760.92-0.83-0.970.960.910.930.860.880.950.680.960.910.930.820.81-0.470.6-0.390.49-0.340.32
0.850.920.86-0.751.0-0.64-0.960.910.690.990.930.670.970.690.960.910.770.730.87-0.420.37-0.360.35-0.290.13
0.990.70.92-0.480.78-0.91-0.850.890.970.820.710.980.860.760.870.930.770.870.7-0.450.62-0.410.67-0.380.36
0.880.560.76-0.40.74-0.76-0.770.680.760.790.830.770.840.690.820.820.730.870.77-0.380.36-0.460.35-0.430.31
0.770.660.67-0.620.87-0.41-0.890.70.570.890.870.550.920.80.910.810.870.70.77-0.550.54-0.240.31-0.180.52
-0.46-0.35-0.40.35-0.430.230.5-0.41-0.4-0.44-0.4-0.4-0.48-0.5-0.5-0.47-0.42-0.45-0.38-0.55-0.540.11-0.290.08-0.53
0.590.380.56-0.430.39-0.38-0.570.550.670.410.260.640.480.560.540.60.370.620.360.54-0.54-0.040.64-0.030.86
-0.41-0.32-0.410.21-0.360.480.34-0.4-0.41-0.35-0.36-0.4-0.39-0.36-0.34-0.39-0.36-0.41-0.46-0.240.11-0.04-0.320.990.09
0.630.270.50.00.38-0.57-0.410.60.680.390.090.720.430.730.470.490.350.670.350.31-0.290.64-0.32-0.320.37
-0.37-0.26-0.360.15-0.30.460.28-0.36-0.39-0.29-0.29-0.38-0.34-0.33-0.28-0.34-0.29-0.38-0.43-0.180.08-0.030.99-0.320.09
0.330.020.21-0.190.14-0.03-0.330.170.350.190.150.320.290.490.330.320.130.360.310.52-0.530.860.090.370.09
Click cells to compare fundamentals

Novavax Account Relationship Matchups

Novavax fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets173.0M1.6B2.6B2.3B1.8B1.9B
Other Current Liab19.9M(327.6M)709.8M1.5B1.3B1.3B
Total Current Liabilities25.8M322.0M2.4B2.5B1.6B1.7B
Total Stockholder Equity(186.0M)627.2M(351.7M)(634.1M)(716.9M)(681.1M)
Property Plant And Equipment Net11.4M180.0M228.7M400.5M491.0M515.5M
Net Debt243.1M(231.4M)(1.1B)(787.1M)(339.4M)(322.5M)
Retained Earnings(1.4B)(1.9B)(3.6B)(4.3B)(4.8B)(4.6B)
Accounts Payable2.9M54.3M127.1M216.5M132.6M139.2M
Cash78.8M553.4M1.5B1.3B568.5M596.9M
Non Current Assets Total75.7M334.3M421.6M555.3M711.5M747.0M
Non Currrent Assets Other7.5M13.2M56.7M28.5M88.1M92.5M
Cash And Short Term Investments78.8M711.0M1.5B1.3B568.5M596.9M
Common Stock Shares Outstanding24.1M57.6M74.4M78.2M100.8M105.8M
Liabilities And Stockholders Equity173.0M1.6B2.6B2.3B1.8B1.9B
Other Current Assets93.9M441.8M176.1M247.5M236.4M248.3M
Other Stockholder Equity1.3B2.5B3.3B3.6B4.1B4.3B
Total Liab359.0M955.3M2.9B2.9B2.5B2.6B
Property Plant And Equipment Gross11.4M180.0M258.6M447.8M566.0M594.3M
Total Current Assets97.2M1.2B2.2B1.7B1.1B1.2B
Accumulated Other Comprehensive Income(12.5M)7.0M(1.4M)(6.4M)2.7M2.9M
Net Receivables7.5M262.0M455.0M82.4M297.2M312.1M
Non Current Liabilities Total333.2M633.2M538.1M432.8M937.1M984.0M
Intangible Assets6.5M5.6M5.7M4.8M4.3M4.1M
Short Long Term Debt Total321.9M322.0M454.0M549.8M229.1M140.8M
Common Stock Total Equity3.8M324K714K764K878.6K1.3M
Short Term Debt1.3M322.0M130.5M352.1M5.1M4.9M
Common Stock324K714K764K868K1.4M1.3M
Long Term Debt320.6M322.0M323.5M166.5M168.0M114.6M
Inventory(83.0M)(166.7M)(2.0B)36.7M41.7M43.8M
Property Plant Equipment11.4M180.0M228.7M400.5M460.6M483.6M
Other Liab2.6M3.4M175.5M185.0M212.8M223.4M
Current Deferred Revenue1.7M273.2M1.4B370.1M241.3M140.2M
Other Assets1.1M5.4M16.6M28.5M(57.9M)(55.0M)
Good Will51.2M135.4M131.5M126.3M127.5M133.8M
Short Term Investments22.0M0.0157.6M10.4M12.0M11.4M
Net Tangible Assets(242.8M)486.1M(487.9M)(760.4M)(684.4M)(650.1M)
Retained Earnings Total Equity(1.3B)(1.4B)(1.9B)(3.6B)(3.3B)(3.1B)
Long Term Debt Total319.2M320.6M322.0M323.5M372.0M234.9M
Capital Surpluse1.1B1.3B2.5B3.4B3.9B4.0B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.